lovastatin has been researched along with Diabetic Glomerulosclerosis in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (44.44) | 18.2507 |
| 2000's | 4 (22.22) | 29.6817 |
| 2010's | 6 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, L; Li, R; Lu, Q; Lu, S; Lyu, L; Ma, Z; Xu, H | 1 |
| Argani, H; Azizi, T; Gholamin, S; Ghorbanihaghjo, A; Rashtchizadeh, N; Razavi, SM; Safa, J; Taghavi-Garmestani, SM; Vatankhah, AM | 1 |
| Ahmadi, F; Mohebi-Nejad, A | 1 |
| Argani, H; Ghorbanihaghjo, A; Montazer-Saheb, S; Nezami, N; Rashtchizadeh, N; Safa, J | 1 |
| Eftekhar-Sadat, AT; Ghorashi, S; Khosraviani, K; Nezami, N; Safa, J; Sakhaee, K; Salari, B | 1 |
| Argani, H; Ghorbanihaghjo, A; Hajhosseini, B; Nezami, N; Rashtchizadeh, N; Safa, J; Salari, B; Vatankhah, AM | 1 |
| Davari-Farid, S; Ghorashi, S; Hashemi-Aghdam, Y; Khosraviani, K; Nargabad, ON; Nezami, N; Safa, J; Salari, B; Tabrizi, JS | 1 |
| Duan, HJ; He, N; Liu, QJ; Liu, SX; Shi, YH; Wang, LH | 1 |
| Duan, HJ; Liu, QJ; Shi, YH; Wang, LH | 1 |
| Cheng, IK; Janus, ED; Lam, KS; Pang, RW | 1 |
| Forsman, JA; Hirst, K; Larsen, JL; Miller, S; Stratta, RJ; Taylor, RJ | 1 |
| Parving, HH | 1 |
| Bender, R | 1 |
| Brouhard, BH; Cressman, MD; Inman, SR; Nally, JV; Satodate, R; Satoh, S; Stowe, NT; Vidt, DG | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Han, DC; Kim, SI; Lee, HB | 1 |
| Andersen, P; Dyerberg, J; Gall, MA; Hommel, E; Jensen, B; Nielsen, F; Parving, HH; Rossing, P | 1 |
| Biesenbach, G; Zazgornik, J | 1 |
1 review(s) available for lovastatin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
4 trial(s) available for lovastatin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Topics: Adult; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Leptin; Lovastatin; Male; Middle Aged | 2014 |
Lovastatin raises serum osteoprotegerin level in people with type 2 diabetic nephropathy.
Topics: Blood Glucose; Demography; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Osteoprotegerin | 2010 |
Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Apoprotein(a); Blood Pressure; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, Diabetic; Female; Follow-Up Studies; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoprotein(a); Lovastatin; Male; Middle Aged; Placebos; Single-Blind Method; Time Factors; Triglycerides | 1995 |
Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.
Topics: Adult; Albuminuria; Analysis of Variance; Apolipoproteins; Blood Glucose; Blood Pressure; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Female; Glomerular Filtration Rate; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Lovastatin; Male; Simvastatin; Triglycerides | 1992 |
13 other study(ies) available for lovastatin and Diabetic Glomerulosclerosis
| Article | Year |
|---|---|
Renal Resistive Index as a Novel Indicator for Renal Complications in High-Fat Diet-Fed Mice.
Topics: Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, High-Fat; Fibrosis; Glomerular Filtration Rate; Kidney; Lovastatin; Male; Mice; Mice, Inbred C57BL; Renal Artery; Ultrasonography | 2017 |
Re: Lovastatin for reduction of leptin in nondialysis patients with type 2 diabetic nephropathy.
Topics: Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Leptin; Lovastatin; Male | 2014 |
C-reactive protein level following treatment and withdrawal of lovastatin in diabetic nephropathy.
Topics: Adult; Aged; C-Reactive Protein; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Triglycerides | 2009 |
Lovastatin enhances paraoxonase enzyme activity and quells low-density lipoprotein susceptibility to oxidation in type 2 diabetic nephropathy.
Topics: Aryldialkylphosphatase; Cholesterol, LDL; Diabetic Nephropathies; Humans; Lipoproteins, LDL; Lovastatin; Oxidation-Reduction | 2011 |
Effect of lovastatin therapy and withdrawal on serum uric acid level in people with type 2 diabetic nephropathy.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fasting; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lovastatin; Male; Middle Aged; Time Factors; Uric Acid; Withholding Treatment | 2012 |
[Effects of lovastatin on renal function and expression of phosphorylating-p38 mitogen-activated protein kinase in experimental diabetic nephropathy in rats].
Topics: Animals; Cyclic AMP Response Element-Binding Protein; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Kidney; Kidney Function Tests; Kidney Glomerulus; Lovastatin; Male; p38 Mitogen-Activated Protein Kinases; Random Allocation; Rats; Rats, Wistar; Signal Transduction | 2004 |
[Protective effects of Lovastatin on early diabetic renal tissue and the possible mechanism].
Topics: Activating Transcription Factor 2; Animals; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Kidney Function Tests; Lovastatin; Male; Protective Agents; Rats; Rats, Wistar | 2005 |
Gender differences in lipid alterations following combined pancreas-kidney transplantation.
Topics: Adrenergic beta-Antagonists; Adult; Cholesterol; Cholesterol, HDL; Creatinine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; Humans; Immunosuppression Therapy; Islets of Langerhans Transplantation; Kidney Transplantation; Lipids; Lovastatin; Male; Menstrual Cycle; Postoperative Period; Prolactin; Renal Insufficiency; Sex Characteristics; Triglycerides | 1994 |
Cholesterol-lowering therapy may retard the progression of diabetic nephropathy.
Topics: Anticholesteremic Agents; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Follow-Up Studies; Glomerular Filtration Rate; Humans; Lovastatin; Proteinuria; Research Design | 1996 |
The effect of cholesterol-lowering therapy on the progression of diabetic nephropathy is unproved.
Topics: Anticholesteremic Agents; Diabetic Nephropathies; Disease Progression; Glomerular Filtration Rate; Humans; Lovastatin; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design | 1996 |
Lovastatin preserves renal function in experimental diabetes.
Topics: Animals; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drug Therapy, Combination; Enalapril; Glomerular Filtration Rate; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Kidney Function Tests; Lovastatin; Male; Rats; Rats, Wistar; Triglycerides | 1999 |
Lovastatin inhibits transforming growth factor-beta1 expression in diabetic rat glomeruli and cultured rat mesangial cells.
Topics: Albuminuria; Animals; Blood Glucose; Cells, Cultured; Cholesterol; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Disease Models, Animal; Fibronectins; Glomerular Mesangium; Kidney Glomerulus; Lovastatin; Male; Mevalonic Acid; Organ Size; Protein Biosynthesis; Rats; Rats, Sprague-Dawley; RNA, Messenger; Streptozocin; Transforming Growth Factor beta | 2000 |
Lovastatin in the treatment of hypercholesterolemia in nephrotic syndrome due to diabetic nephropathy stage IV-V.
Topics: Adult; Aged; Cholesterol; Creatinine; Diabetic Nephropathies; Female; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Triglycerides | 1992 |